Niacin

"Niacin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.

Descriptor ID	D009525
MeSH Number(s)	D03.066.515.475 D03.383.725.547.475
Concept/Terms	Niacin Niacin Nicotinic Acid 3-Pyridinecarboxylic Acid 3 Pyridinecarboxylic Acid Niacin Lithium Salt, Hemihydrate Niacin Lithium Salt, Hemihydrate Niacin Potassium Salt Niacin Potassium Salt Potassium Salt, Niacin Niacin Sodium Salt Niacin Sodium Salt Sodium Salt, Niacin Niacin Tartrate Niacin Tartrate Tartrate, Niacin Niacin Copper (2+) Salt Niacin Copper (2+) Salt Niacin Hydrochloride Niacin Hydrochloride Hydrochloride, Niacin Niacin Iron (2+) Salt Niacin Iron (2+) Salt Niacin Tosylate Niacin Tosylate Tosylate, Niacin Niacin Zinc Salt Niacin Zinc Salt Nicamin Nicamin Nico-400 Nico-400 Nico 400 Nico400 Nicobid Nicobid Nicocap Nicocap Nicolar Nicolar Nicotinate Nicotinate Wampocap Wampocap Enduracin Enduracin Induracin Induracin Niacin Calcium Salt Niacin Calcium Salt Lithium Nicotinate Lithium Nicotinate Nicotinate, Lithium Niacin Aluminum Salt Niacin Aluminum Salt Aluminum Salt, Niacin Niacin Ammonium Salt Niacin Ammonium Salt Niacin Lithium Salt Niacin Lithium Salt Niacin Cobalt (2+) Salt Niacin Cobalt (2+) Salt Niacin Magnesium Salt Niacin Magnesium Salt Niacin Manganese (2+) Salt Niacin Manganese (2+) Salt

Below are MeSH descriptors whose meaning is more general than "Niacin".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Acids, Heterocyclic [D03.066]
Nicotinic Acids [D03.066.515]
Niacin [D03.066.515.475]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyridines [D03.383.725]
Nicotinic Acids [D03.383.725.547]
Niacin [D03.383.725.547.475]

Below are MeSH descriptors whose meaning is related to "Niacin".

Below are MeSH descriptors whose meaning is more specific than "Niacin".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Niacin" by people in this website by year, and whether "Niacin" was a major or minor topic of these publications.

Bar chart showing 16 publications over 11 distinct years, with a maximum of 4 publications in 2003

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	1	0	1
2003	4	0	4
2004	1	0	1
2007	0	1	1
2008	1	0	1
2010	1	0	1
2011	1	0	1
2012	0	1	1
2013	1	1	2
2016	1	0	1
2017	1	1	2

Below are the most recent publications written about "Niacin" by people in Profiles.

Skolnik N, Jaffa FM, Kalyani RR, Johnson E, Shubrook JH. Reducing CV risk in diabetes: An ADA update. J Fam Pract. 2017 May; 66(5):300-308.

View in: PubMed
Gaynon MW, Paulus YM, Rahimy E, Alexander JL, Mansour SE. Effect of oral niacin on central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2017 Jun; 255(6):1085-1092.

View in: PubMed
Rahimy E, Gaynon MW, Paulus YM, Alexander JL, Mansour SE. Potentially Reversible Effect of Niacin Therapy on Edema From Retinal Vein Occlusion. JAMA Ophthalmol. 2016 07 01; 134(7):839-40.

View in: PubMed
Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O'Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WE. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013 Oct 22; 62(17):1580-4.

View in: PubMed
Teo KK, Goldstein LB, Chaitman BR, Grant S, Weintraub WS, Anderson DC, Sila CA, Cruz-Flores S, Padley RJ, Kostuk WJ, Boden WE. Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. Stroke. 2013 Oct; 44(10):2688-93.

View in: PubMed
Gadi R, Amanullah A, Figueredo VM. HDL-C: does it matter? An update on novel HDL-directed pharmaco-therapeutic strategies. Int J Cardiol. 2013 Aug 10; 167(3):646-55.

View in: PubMed
Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011 Dec 15; 365(24):2255-67.

View in: PubMed
Lai E, Schwartz JI, Dallob A, Jumes P, Liu F, Kraft WK, Royalty J, Chodakewitz JA, McCrary Sisk C, Radziszewski W, Wagner JA. Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects. Platelets. 2010; 21(3):191-8.

View in: PubMed
Tittler EH, de Barros DS, Navarro JB, Freitas DG, Gheith ME, Siam GA, Spaeth GL. Oral niacin can increase intraocular pressure. Ophthalmic Surg Lasers Imaging. 2008 Jul-Aug; 39(4):341-2.

View in: PubMed
Codario RA. Hypertriglyceridemia and cardiovascular disease management. J Am Acad Nurse Pract. 2007; 19(12 Suppl 2):7-10, 13-4.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement